PCR testing company Vela Diagnostics reported on Tuesday the receipt of the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the ViroKey SARS-CoV-2 RT-PCR Test v2.0 to detect SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs.
Vela Diagnostics said its automated probe-based reverse transcription PCR test detects SARS-CoV-2, the coronavirus responsible for COVID-19. Laboratories in the US certified under the Clinical Laboratory Improvement Amendments can use the test for COVID-19 detection.
According to the company, the ViroKey SARS-CoV-2 RT-PCR Test v2.0 is an automated probe-based reverse transcription PCR test optimized for a workflow consisting of its Sentosa SX101 and the Sentosa SA201 instrument (or ABI 7500 Fast Dx). The automated test enables high throughput testing of up to 46 samples in a single run, with reduced hands-on time.
In addition, the company's ViroKey SARS-CoV-2 RT-PCR Test v2.0 has received the CE mark and Provisional Authorisation from the Singapore Health Sciences Authority.
RB Medical Supply announces VTM collection kit to facilitate COVID-19 testing
Qualigen to begin clinical development of AS1411 for COVID-19 upon FDA's Pre-IND positive response
Regeneron's COVID-19 antibody treatment shown to cut medical visits in a clinical trial
COVID-19 vaccines free for all Americans that is authorised or approved by US FDA
Enhertu Granted Priority Review in the US for Treatment of HER2 Positive Metastatic Gastric Cancer
Eli Lilly signs USD375 deal with US government to supply 300,000 vials of potential COVID-19 drug